WO2000009710A3 - Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists - Google Patents

Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists Download PDF

Info

Publication number
WO2000009710A3
WO2000009710A3 PCT/CA1999/000734 CA9900734W WO0009710A3 WO 2000009710 A3 WO2000009710 A3 WO 2000009710A3 CA 9900734 W CA9900734 W CA 9900734W WO 0009710 A3 WO0009710 A3 WO 0009710A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
antagonists
agonists
malonyl coa
Prior art date
Application number
PCT/CA1999/000734
Other languages
French (fr)
Other versions
WO2000009710A2 (en
Inventor
Gary D Lopaschuk
Jason Dyck
Original Assignee
Univ Alberta
Gary D Lopaschuk
Jason Dyck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta, Gary D Lopaschuk, Jason Dyck filed Critical Univ Alberta
Priority to JP2000565145A priority Critical patent/JP2002522082A/en
Priority to CA002339088A priority patent/CA2339088A1/en
Priority to EP99938082A priority patent/EP1127139A2/en
Priority to KR1020017001831A priority patent/KR20010085373A/en
Priority to AU52729/99A priority patent/AU774628B2/en
Publication of WO2000009710A2 publication Critical patent/WO2000009710A2/en
Publication of WO2000009710A3 publication Critical patent/WO2000009710A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Definitions

  • VOILLEY N ET AL "Cloning and expression of rat pancreatic beta-cell malonyl - CoA decarboxylase.” retrieved from STN

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the area of fatty acid oxidation, generally to compositions and methods of identifying and testing fatty acid oxidation inhibitors, and in particular, compositions comprising a novel cardiac isoform of MCD, identified to be a key regulator of fatty acid oxidation in the heart. Additionally, nucleic acid sequences of malonyl CoA decarboxylase genes from the rat pancreas, heart and liver are described. Such sequences and derived products are useful in screening methods for identifying and testing agonists and antagonists of the MCD pathway.

Description

. _
Category ° Citation of document, with indication, where appropπate, of the relevant passages Relevant to claim No.
P,X DATABASE MEDLINE [Onl i ne] 21-25
US NATIONAL LIBRARY OF MEDICINE (NLM) ,
BETHESDA, MD, US
VOILLEY N ET AL: "Cloning and expression of rat pancreatic beta-cell malonyl - CoA decarboxylase." retrieved from STN
Database accession no. 1999247914
XPO02124721 cited in the application
& BIOCHEMICAL JOURNAL, (1999 MAY 15) 340 ( PT 1) 213-7. ,
MITZEN ET AL.: "Malonate, 1-20
Malonyl-Coenzyme A, and Acetyl -Coenzyme A in Developing Rat Brain."
J. NEUROCHEM., vol. 43, no. 2, 1984, pages 499-506,
XP000857197 page 503; figure 1
Form PCT/ISA 210 (continuation of second sheet) (July 1992) page 2 of 2
PCT/CA1999/000734 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists WO2000009710A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000565145A JP2002522082A (en) 1998-08-11 1999-08-09 Compositions and methods for identifying inhibitors, agonists and antagonists of mammalian malonyl-CoA decarboxylase
CA002339088A CA2339088A1 (en) 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
EP99938082A EP1127139A2 (en) 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
KR1020017001831A KR20010085373A (en) 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
AU52729/99A AU774628B2 (en) 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9609398P 1998-08-11 1998-08-11
US25120099A 1999-02-16 1999-02-16
US60/096,093 1999-02-16
US09/251,200 1999-02-16

Publications (2)

Publication Number Publication Date
WO2000009710A2 WO2000009710A2 (en) 2000-02-24
WO2000009710A3 true WO2000009710A3 (en) 2001-06-07

Family

ID=26791076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000734 WO2000009710A2 (en) 1998-08-11 1999-08-09 Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists

Country Status (6)

Country Link
EP (1) EP1127139A2 (en)
JP (1) JP2002522082A (en)
KR (1) KR20010085373A (en)
AU (1) AU774628B2 (en)
CA (1) CA2339088A1 (en)
WO (1) WO2000009710A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4155351B2 (en) * 2001-02-20 2008-09-24 中外製薬株式会社 Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic regulators
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
BR0311161A (en) * 2002-05-21 2005-03-29 Cv Therapeutics Inc Diabetes Treatment Method
EP2208495B1 (en) 2003-08-01 2011-12-14 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
ATE400272T1 (en) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd PIPERIDINE COMPOUNDS AS MALONYL-COA DECARBOXYLASE INHIBITORS
DE602004009582T2 (en) 2003-08-01 2009-01-02 Chugai Seiyaku K.K. CYANOAMIDE COMPOUNDS AS USEFUL MALONYL COA DECARBOXYLASE HEMMER
WO2008106630A1 (en) * 2007-03-01 2008-09-04 Bristol-Myers Squibb Company Coupled enzyme assay for measuring acetyl coa carboxylase and malonyl coa decarboxylase activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL JOURNAL, (1999 MAY 15) 340 ( PT 1) 213-7. *
BONALDO ET AL.: "Normalization and Substraction: Two Approaches to Facilitate Gene Discovery.", GENOME RES., vol. 6, September 1996 (1996-09-01), pages 791 - 806, XP002039972 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; VOILLEY N ET AL: "Cloning and expression of rat pancreatic beta-cell malonyl - CoA decarboxylase.", XP002124721, retrieved from STN Database accession no. 1999247914 *
DYCK ET AL.: "Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation.", AM. J. PHYSIOL., vol. 44, no. 6, December 1998 (1998-12-01), pages H2122 - H2129, XP000857359 *
MITZEN ET AL.: "Malonate, Malonyl-Coenzyme A, and Acetyl-Coenzyme A in Developing Rat Brain.", J. NEUROCHEM., vol. 43, no. 2, 1984, pages 499 - 506, XP000857197 *

Also Published As

Publication number Publication date
KR20010085373A (en) 2001-09-07
CA2339088A1 (en) 2000-02-24
AU5272999A (en) 2000-03-06
WO2000009710A2 (en) 2000-02-24
EP1127139A2 (en) 2001-08-29
AU774628B2 (en) 2004-07-01
JP2002522082A (en) 2002-07-23

Similar Documents

Publication Publication Date Title
Markert et al. Lactate dehydrogenase isozyme patterns of fish
Löwik et al. A two-receptor model for the action of parathyroid hormone on osteoblasts: a role for intracellular free calcium and cAMP
Derrick et al. L-carnitine acyltransferase in intact peroxisomes is inhibited by malonyl-CoA
Tollefsbol et al. Werner’s syndrome: an underdiagnosed disorder resembling premature aging
JP2002543422A (en) Indicators of altered mitochondrial function in predictive methods for determining the risk of type 2 diabetes
Fluck et al. Acetylcholinesterase activity in developing skeletal muscle cells in vitro
CA2363486A1 (en) Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
Enríquez et al. The synthesis of mRNA in isolated mitochondria can be maintained for several hours and is inhibited by high levels of ATP
Pisoni et al. Important differences in cationic amino acid transport by lysosomal system c and system y+ of the human fibroblast.
WO2000009710A3 (en) Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists
Høj et al. Partial separation of individual enzyme activities of an ACP-dependent fatty acid synthetase from barley chloroplasts
Jaken Measurement of phorbol ester receptors in intact cells and subcellular fractions
Kawakubo et al. Properties of cutaneous acetyltransferase catalyzing N-and O-acetylation of carcinogenic arylamines and N-hydroxyarylamine
Sen et al. Enhanced alpha 1-adrenergic responsiveness in cardiomyopathic hamster cardiac myocytes. Relation to the expression of pertussis toxin-sensitive G protein and alpha 1-adrenergic receptors.
Ganschow et al. Glucuronidase phenotypes of inbred mouse strains
Appels et al. Chemical and structural changes within chick erythrocyte nuclei introduced into mammalian cells by cell fusion
Medley et al. Dictyostelium myosin-II heavy-chain kinase A is activated by autophosphorylation: studies with Dictyostelium myosin-II and synthetic peptides
Salem et al. Fatty acid ethyl esters in liver and adipose tissues as postmortem markers for ethanol intake
Zelenka et al. Transmethylation of phosphatidylethanolamine: an initial event in embryonic chicken lens fiber cell differentiation
Uotila et al. Multiple forms of formaldehyde dehydrogenase from human red blood cells
Shumaker et al. Cryptic variability at enzyme loci in three plant species, Avena barbata, Hordeum vulgare, and Zea mays
Lecka-Czernik et al. Cellular and molecular biomarkers indicate precocious in vitro senescence in fibroblasts from SAMP6 mice: evidence supporting a murine model of premature senescence and osteopenia
Slonczewski et al. Phosphorylase a activity as an indicator of neutrophil activation by chemotactic peptide.
Stathopoulos et al. Identification of two cytosolic diacylglycerol kinase isoforms in rat brain, and in NIH-3T3 and ras-transformed fibroblasts
Kim et al. Inhibition of progesterone-induced Xenopus oocyte maturation by Nm23

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2339088

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2339088

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020017001831

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 565145

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 52729/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999938082

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1999938082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017001831

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 52729/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999938082

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001831

Country of ref document: KR